In recent decades, rapid progression of monoclonal antibody (mAb) development has culminated in approvals for more than one hundred therapeutics in the United States. mAbs enhance the immune response ...
Pembrolizumab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I.
Research and development of monoclonal antibody (mAb) therapeutics is a vast and expanding area of drug discovery, largely due to mAb potential for high specificity and affinity towards target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results